2023 agenda

Friday May 12, 2023

7:00 – 8:00 Breakfast
8:00 – 8:05 Welcome to CMHCC Dr. Brandon Meyers (ON)
8:05 – 10:00 Early Stage Disease Chair: Dr. Chaya Shwaartz (ON)
8:05 – 8:20 The Change in the BCLC Criteria  Dr. Robert Grant (ON)
8:20 – 8:25 Question and Answer Period with Audience
8:25 – 8:55 Resection- Where to Draw the Line  Dr. Daniel Azoulay (France)
8:55 – 9:05 Question and Answer Period with Audience
9:05 – 9:20 Transplant – Is There  Room for Transplant in Early-Stage HCC?  Dr. Chaya Shwaartz (ON)
9:20 – 9:25 Question and Answer Period with Audience
9:25 – 9:40 Non-Surgical Techniques for Curative Intent   Dr. John Kachura (ON)
9:40 – 9:45 Question and Answer Period with the Audience
9:45 – 10:05 Early Stage Disease Panel Discussion/Cases with Audience Chair: Dr. Chaya Shwaartz,
Panel: Dr. Daniel Azoulay, Dr. Michael Lock,
Dr. Robert Grant, Dr. Trevor Reichman
10:05 – 10:30 Refreshment Break
10:30 – 12:00 Intermediate/Locally Advanced Stage Disease Chair: Dr. Anand Swaminath (ON)
10:30 – 10:35 Welcome and Introductions ( Pre Debate Vote) Dr. Anand Swaminath
10:35 – 11:10 Debate: Y90 vs External Beam RT Dr. Michael Lock and Dr. David Liu
10:35 – 10:45 Y 90 Dr. David Liu (BC)
10:45 – 10:55 External Beam RT Dr. Michael Lock (ON)
10:55 – 11:05 Rebuttals Dr. Michael Lock and Dr. Dave Liu
11:05 – 11:10 Voting/ Discussion with Audience
11:10 – 11:45 Case Based Panel Discussion with Audience Chair: Dr. Anand Swaminath,
Panel: Dr. Michael Lock, Dr. David Liu,
Dr. Brandon Meyers, Dr. Chaya Shwaartz
11:45 – 13:00 Lunch
13:00 – 16:00 Afternoon Sessions Dr. Vincent Tam (AB)
13:05 – 13:50 Keynote: Advents in the Treatment of Hepatocellular Carcinoma. Where Are We Going? Dr. Ghassan Abou-Alfa (NY, USA)
13:50 – 14:05 Question and Answer Period
14:05 – 14:25 Refreshment Break
14:25 – 16:10 Advanced Stage Disease  Chair: Dr. Rachel Goodwin (ON)
14:25 – 14:45 Trial Review Dr. Ravi Ramjeesingh (NS)
14:45 – 14:50 Question and Answer Period
14:50 – 15:20 Debate:
Dual Immunotherapy versus Checkpoint Inhibitor + VEGF Inhibitor in First-Line Treatment of HCC
Dual Immunotherapy -Dr. Vincent Tam
Checkpoint Inhib. + VEGF – Dr. Brandon Meyers
15:20 – 15:40 Voting and Question Period with the Audience
15:40 – 16:10 Advanced Stage Panel Discussion with Audience Chair: Dr. Rachel Goodwin,
Panel: Dr. Ghassan Abou-Alfa, Dr. Jennifer Knox,
Dr. Vincent Tam, Dr. Anand Swaminath
16:10 – 16:15 Closing Remarks Dr. Vincent Tam